Timing of SGLT2 inhibitors (SGLT2i) initiation after acute myocardial infarction
Authors' conclusion
Very early administration of SGLT2i after acute myocardial infarction does not show disadvantageous signals with respect to safety and appears to be as effective in reducing NT-proBNP as well as improving structural and functional LV markers as initiation after 2-3 days.
Study context
- Population
- Patients with acute MI after PCI in the Empagliflozin group of the EMMY trial
- Participants
- 22 / 98 / 111
- Comparison
- Early vs intermediate vs late empagliflozin initiation after PCI
- Earlyn = 22
- Intermediaten = 98
- Laten = 111reference
- Primary endpoint
- NT-proBNP decline
Primary result
As reported in the abstract
Pint = 0.96
Secondary outcomes
LV function (left ventricular function (LV-EF), e/e`) and structure (LVESD, LVEDD)
- Comparable between the initiation time groups
Safety
- No significant difference in severe adverse event rate between the initiation time groups
Original publication
Timing of SGLT2i initiation after acute myocardial infarction. Cardiovasc Diabetol. Published 30 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →